Samson Clinical Announces Last Patient Last Visit in its Pivotal Phase III Study of Sublingual Minoxidil for Male Androgenetic Alopecia

MELBOURNE, Australia, May 18, 2026 /PRNewswire/ -- Samson Clinical Operations Pty Ltd (Samson) announced completion of the Last Patient Last Visit in its pivotal Phase III clinical trial evaluating low dose sublingual minoxidil in male Androgenetic Alopecia (AGA)(SAM-002). Topline results...

Read More